Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DNL747 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DNL747 First, Placebo Second | EXPERIMENTAL | Subjects will receive DNL747 for 29 days for the first period and then will switch to placebo for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods. |
| Placebo First, DNL747 Second | EXPERIMENTAL | Subjects will receive placebo for 29 days for the first period and then will switch to DNL747 for 29 days for the second period. There will be a 14-day washout period between the 2 treatment periods. |
| Name | Type | Description |
|---|---|---|
| DNL747 | DRUG | DNL747 |
| Placebo | DRUG | Placebo |
Key Inclusion Criteria: * Women of non-childbearing potential and men, aged 55-85 years * AD diagnosis based on the 2011 National Institute on Aging-Alzheimer's Association Guidelines * Supportive evidence for diagnosis of AD based upon positive CSF Aβ42 test, or documented history of positive amyl...
Top 20 of 24 competitors
DNL747 is an investigational small molecule being developed for the treatment of Alzheimer's disease. It is designed to address the underlying disease process in patients with this condition. The drug is currently in clinical development and has not been approved for use.
DNL747 is being developed by Denali Therapeutics Inc., a biopharmaceutical company publicly traded under the ticker symbol DNLI. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for Alzheimer's disease.
DNL747 is in Phase 1 clinical development. A Phase 1 study of the drug has been completed, which involved 16 participants with Alzheimer's disease. The drug remains investigational and is not yet approved for commercial use.
DNL747 has been studied in a Phase 1 clinical trial identified as NCT03757325, titled "Study to Evaluate DNL747 in Subjects With Alzheimer's Disease." This randomized, double-blind, controlled study enrolled 16 participants and was conducted in the United States and Netherlands.
DNL747 is a distinct investigational drug candidate developed by Denali Therapeutics. It is not known to be the same as any other approved or marketed medication. Its unique molecular identity is being evaluated specifically for its potential role in treating Alzheimer's disease.